158 related articles for article (PubMed ID: 27951496)
21. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
22. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
23. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
24. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein.
Kawahara B; Ramadoss S; Chaudhuri G; Janzen C; Sen S; Mascharak PK
J Inorg Biochem; 2019 Feb; 191():29-39. PubMed ID: 30458366
[TBL] [Abstract][Full Text] [Related]
25. Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line.
Shibata K; Umezu T; Sakurai M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Obstet Invest; 2011; 71(2):104-11. PubMed ID: 21150160
[TBL] [Abstract][Full Text] [Related]
26. [The expression of glutathione S-transferase pi in human ovarian cancer as an indicator of resistance to chemotherapy].
Li L; Yao D; Chen X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):95-7. PubMed ID: 10682429
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
28. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin.
Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI
Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.
Poulain L; Lincet H; Duigou F; Deslandes E; Sichel F; Gauduchon P; Staedel C
Int J Cancer; 1998 Nov; 78(4):454-63. PubMed ID: 9797134
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
Fajac A; Da Silva J; Ahomadegbe JC; Rateau JG; Bernaudin JF; Riou G; Bénard J
Int J Cancer; 1996 Sep; 68(1):67-74. PubMed ID: 8895543
[TBL] [Abstract][Full Text] [Related]
32. Comparative genomic hybridization analysis of cisplatin-resistant ovarian carcinoma cells.
Arai R; Ghazizadeh M; Kawanami O
J Nippon Med Sch; 2000 Dec; 67(6):416-7. PubMed ID: 11116235
[No Abstract] [Full Text] [Related]
33. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
36. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
37. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
[TBL] [Abstract][Full Text] [Related]
39. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.
Zheng ZG; Xu H; Suo SS; Xu XL; Ni MW; Gu LH; Chen W; Wang LY; Zhao Y; Tian B; Hua YJ
Sci Rep; 2016 May; 6():26093. PubMed ID: 27193186
[TBL] [Abstract][Full Text] [Related]
40. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
